Prostate cancer with multiple lung metastases in a hemodialysis patient

Abstract

In hemodialysis patients, few cases of prostate cancer have been reported until recently. We present a case of prostate cancer with multiple lung metastases in a chronic hemodialysis patient. A 65-year-old Japanese man who had maintained hemodialysis for 5 years was referred to our hospital with multiple metastatic lung tumors. Serum prostate tumor markers were highly elevated although his plasma testosterone level was within the normal range. A transrectal needle prostate biopsy confirmed a histologic diagnosis of moderately differentiated adenocarcinoma. Androgen blockade therapy was very effective as evidenced by a quick decrease of serum tumor markers. The followup computed tomography scan of the chest performed 3 months later showed a complete disappearance of the coin lesions. The early detection of prostate cancer in hemodialysis patients is difficult because of a lack of urologic symptoms, which indicate the importance of periodic screening by serum tumor markers. Combined androgen blockade is effective even in hemodialysis patients. However, close follow up is necessary because long-term results and prognoses are still unknown.

Comparison of Stage at Diagnosis of Cancer in Patients Who Are on Dialysis versus the General Population

“…This may be in part due to lower use of PSA screening in the ESRD population, demonstrated both in this study and in previous work (8,9). In addition, the absence of urinary output may hinder early diagnosis on the basis of urinary tract symptoms (22). Despite the poor outcome in distant disease, it is still unclear whether PSA screening reduces mortality in the general population (23).…”

Mass screening for prostate cancer in patients with end‐stage renal disease: a comparative study

“…so-called stage migration [1]. However, most patients with ESRD and prostate cancer have advanced prostate cancer, even after the advent of PSA testing [15].…”

Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?

“…There are several confounding factors which may affect the diagnosis and evaluation of cancer in ESRD such as delayed symptomatic presentation, a non-validated and unclear utility of tumor markers, dilemmas in imaging studies, and lack of prognostic data. Several important cancer presentations may be omitted in ESRD such as hypercalcemia, hyperphosphatemia, pruritus, anemia with severity inadequate to the kidney function and oliguria/anuria [ 118 ]. Serum cancer antigen 125 (CA-125) may be a useful tumor marker however, it can be elevated in ascites, even in non-malignant settings [ 119 ].…”